Sonnet biotherapeutics to present sb221 as a trial in progress at the asco 2024 annual meeting

Princeton, n.j., may 28, 2024 (globe newswire) -- sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that the sb221 study of son-1010 (recombinant human interleukin-12 linked to sonnet's fully-human albumin binding domain or il12-fhab) dosed in combination with atezolizumab (tecentriq®) will be presented as a ‘trial in progress' poster at asco 2024. study sb221 (nct05756907) is a phase 1b/2a multicenter, dose-escalation, and proof-of-concept clinical study to assess the safety, tolerability, pk, pd, and efficacy of son-1010 administered sc, either alone or in combination with a fixed dose of atezolizumab given iv. the work will be presented in a poster session at the upcoming american society of clinical oncology (asco) annual meeting 2024, to be held may 31 to june 4 in chicago, illinois.
SONN Ratings Summary
SONN Quant Ranking